Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
मुख्य लेखकों: | Coates, LC, Garrood, T, Gullick, N, Helliwell, P, Kent, T, Marks, J, Tillett, W, Kaur-Papadakis, D, Tahir, H, van Haaren, S, McInnes, I |
---|---|
स्वरूप: | Journal article |
भाषा: | English |
प्रकाशित: |
Oxford University Press
2022
|
समान संसाधन
-
Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
द्वारा: Coates, LC, और अन्य
प्रकाशित: (2021) -
Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
द्वारा: McGagh, D, और अन्य
प्रकाशित: (2020) -
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
द्वारा: Iain B. McInnes, और अन्य
प्रकाशित: (2022-10-01) -
Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA
द्वारा: Loredana Frasca, और अन्य
प्रकाशित: (2018-09-01) -
Treat-to-target in PsA: methods and necessity
द्वारा: Dures, E, और अन्य
प्रकाशित: (2020)